Cargando…
The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
BACKGROUND: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. METHODS: We con...
Autores principales: | Rhee, Moo-Yong, Ahn, Taehoon, Chang, Kiyuk, Chae, Shung Chull, Yang, Tae-Hyun, Shim, Wan Joo, Kang, Tae Soo, Ryu, Jae-Kean, Nah, Deuk-Young, Park, Tae-Ho, Chae, In-Ho, Park, Seung Woo, Lee, Hae-Young, Tahk, Seung-Jea, Yoon, Young Won, Shim, Chi Young, Shin, Dong-Gu, Seo, Hong Seog, Lee, Sung Yun, Kim, Doo Il, Kwan, Jun, Joo, Seung-Jae, Jeong, Myung Ho, Jeong, Jin-Ok, Sung, Ki Chul, Kim, Seok Yeon, Kim, Sang-Hyun, Chun, Kook-Jin, Oh, Dong Joo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217661/ https://www.ncbi.nlm.nih.gov/pubmed/28057081 http://dx.doi.org/10.1186/s40360-016-0112-7 |
Ejemplares similares
-
Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018) -
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
por: Lee, Hae-Young, et al.
Publicado: (2017) -
Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016) -
Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial
por: Kang, Min-gu, et al.
Publicado: (2019) -
Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)